Shinje Moon1,2, Min Joo Kim3, Jae Myung Yu1, Hyung Joon Yoo1, Young Joo Park3,4. 1. 1 Department of Internal Medicine, Hallym University College of Medicine , Seoul, Republic of Korea. 2. 2 Department of Internal Medicine, Graduate School, Hanyang University , Seoul, Republic of Korea. 3. 3 Department of Internal Medicine, Seoul National University Hospital , Seoul, Republic of Korea. 4. 4 Department of Internal Medicine, Seoul National University , Seoul, Republic of Korea.
Abstract
OBJECTIVES: To determine the impact of subclinical hypothyroidism (SCH) on the risk of cardiovascular disease (CVD) and all-cause mortality, a comprehensive meta-analysis was performed according to the age or coexisting CVD risk status of the participants. METHODS: Studies regarding the association of SCH with all-cause mortality from PubMed and Embase databases were included. The pooled relative risk (RR) of CVD and all-cause mortality was calculated using the Mantel-Haenszel method. A subgroup analysis of participants with high CVD risk was conducted, including history of coronary, cerebral, or peripheral artery disease; dilated cardiomyopathy; heart failure; atrial fibrillation; venous thromboembolism; diabetes mellitus; or chronic kidney disease. RESULTS: In total, 35 eligible articles incorporating 555,530 participants were included. SCH was modestly associated with CVD and all-cause mortality (RR for CVD = 1.33 [confidence interval (CI) 1.14-1.54]; RR for all-cause mortality = 1.20 [CI 1.07-1.34]). However, the association was not observed in participants aged ≥65 years. Subgroup analysis showed that participants with SCH and high CVD risk showed a significantly higher risk of all-cause mortality (RR for CVD = 2.20 [CI 1.28-3.77]; RR for all-cause mortality = 1.66 [CI 1.41-1.94]), whereas those with SCH and low CVD risk did not. Additional subgroup analysis of six studies with a mean participant age of ≥65 years and high CVD risk showed a significant high risk of all-cause mortality in the SCH group (RR = 1.41 [CI 1.08-1.85]; I2 = 0%). CONCLUSIONS: SCH is associated with an increased CVD risk and all-cause mortality, particularly in participants with high CVD risk.
OBJECTIVES: To determine the impact of subclinical hypothyroidism (SCH) on the risk of cardiovascular disease (CVD) and all-cause mortality, a comprehensive meta-analysis was performed according to the age or coexisting CVD risk status of the participants. METHODS: Studies regarding the association of SCH with all-cause mortality from PubMed and Embase databases were included. The pooled relative risk (RR) of CVD and all-cause mortality was calculated using the Mantel-Haenszel method. A subgroup analysis of participants with high CVD risk was conducted, including history of coronary, cerebral, or peripheral artery disease; dilated cardiomyopathy; heart failure; atrial fibrillation; venous thromboembolism; diabetes mellitus; or chronic kidney disease. RESULTS: In total, 35 eligible articles incorporating 555,530 participants were included. SCH was modestly associated with CVD and all-cause mortality (RR for CVD = 1.33 [confidence interval (CI) 1.14-1.54]; RR for all-cause mortality = 1.20 [CI 1.07-1.34]). However, the association was not observed in participants aged ≥65 years. Subgroup analysis showed that participants with SCH and high CVD risk showed a significantly higher risk of all-cause mortality (RR for CVD = 2.20 [CI 1.28-3.77]; RR for all-cause mortality = 1.66 [CI 1.41-1.94]), whereas those with SCH and low CVD risk did not. Additional subgroup analysis of six studies with a mean participant age of ≥65 years and high CVD risk showed a significant high risk of all-cause mortality in the SCH group (RR = 1.41 [CI 1.08-1.85]; I2 = 0%). CONCLUSIONS:SCH is associated with an increased CVD risk and all-cause mortality, particularly in participants with high CVD risk.
Authors: Benjamin Van Tassell; George F Wohlford; Joyce D Linderman; Sheila Smith; Sahzene Yavuz; Frank Pucino; Francesco S Celi Journal: Thyroid Date: 2019-09-12 Impact factor: 6.568
Authors: J Rosenfarb; N Sforza; R Rujelman; Y Morosan Allo; C Parisi; E Blanc; C Frigerio; P Fossati; D Caruso; C Faingold; T Meroño; G Brenta Journal: J Endocrinol Invest Date: 2018-10-26 Impact factor: 4.256